Press Release

SAN FRANCISCO, Calif., April 25, 2022 – Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered protein targets with novel molecular glues, today announced the appointment of Gideon Bollag, Ph.D., to its Scientific Advisory Board. Dr. Bollag brings extensive experience in structure-based drug discovery and the development of oncology therapeutics. “This is a perfect moment to welcome Gideon […]

Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target class Initial discovery pipeline focused on high-value targets in oncology SAN FRANCISCO, Calif., January 06, 2022 – Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment